Award
National Cancer Institute 5UG3CA301294-02
Engineered probiotic bacteria for colorectal cancer immunoprevention and interception
Recipient
Columbia University Health Sciences, New York, NY
Award Amount
$727,904.00
Ceiling
$727,904.00
Awarded
June 11, 2026
Identifier
5UG3CA301294-02
The award funds research to engineer probiotic bacteria as immunotherapies to prevent and intercept colorectal cancer progression by targeting precancerous lesions and modulating immune responses.
Description
This project involves engineering probiotic bacteria to target and prevent colorectal cancer progression using advanced genetic and immunological techniques. The project aims to develop effective probiotic-based immunotherapies that prevent and halt colorectal cancer progression by harnessing engineered E. coli Nissle 1917 strains. The research includes characterizing stage-specific colonization and immune responses, and designing immunotherapeutic bacteria for prevention and interception of colorectal cancer.